

IFW

Docket No. PRD-2033



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Richard L. Apodaca et al.  
Serial No. : 10/690,115 Art Unit:  
Filed : October 21, 2003 Examiner:  
For : PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND  
BENZTHIOAMIDES

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner For Patents, Arlington, VA 22202 on

August 26, 2005  
(Date of Deposit)

John W. Harbour  
(Name of applicant, assignee, or Registered Representative)

/John W. Harbour/  
(Signature)

August 26, 2005  
(Date of Signature)

Commissioner for Patents  
Arlington, VA 22202

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on  
4/30/2004.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98,  
information relating to the above-identified application is hereby disclosed. Inclusion of  
information in this statement is not to be construed as an admission that this information is  
material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed  
invention over any of the information provided herewith, and/or to prove that this

The PTO did not receive the following  
listed items(s) NPL

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e) (attached); or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

☐ Statement in Accordance with §1.97(e) (attached); or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for

consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).

☐ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed .

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD2033/JWH. This form is submitted in triplicate.

Respectfully submitted,

/John W. Harbour/  
John W. Harbour  
Reg. No. 31,365  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-2169  
DATED: August 26, 2005



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Richard L. Apodaca et al.

Serial No. : 10/690,115

Art Unit:

Filed : October 21, 2003

Examiner:

For : PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND  
BENZTHIOAMIDES

Commissioner for Patents  
Arlington, VA 22202

**LETTER**

Dear Sir:

The compound pictured in Example #43 was purchased on a non confidential basis from Asinex, www.asinex.com, a vendor of compound libraries, under stock number BAS 2961222, sometime before June 27, 2001 by 3-Dimenisional Pharmaceuticals. 3-Dimenisional Pharmaceuticals was acquired by Applicant's employer in March 2003. The Examiner should consider these facts in the examination of the pending claims.

Respectfully submitted,

/John W. Harbour

John W. Harbour

Reg. No. 31,365

Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-2169  
DATED: August 26, 2005

